Navigation Links
Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
Date:9/13/2009

t or end of clinical trials and commercial launch of new drugs may be delayed or unsuccessful due to regulatory delays, clinical trial design, slower than anticipated patient enrollment, drug manufacturing challenges, changing standards of care, clinical outcomes, or delay or failure in obtaining regulatory approval in one or more important markets; (iii) the company's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or intellectual property licenses from third parties may be required in the future; (iv) the outcome of any existing or future intellectual property or other litigation related to the company's proprietary product candidates; and (v) the timing and success of the company's efforts to establish and maintain future collaboration partnerships on attractive commercial terms or at all. Other important risks and uncertainties are detailed in the company's reports and other filings with the Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K.

Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise. For more information on Nektar Therapeutics, please visit http://www.nektar.com.

Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise. For more information on Nektar Therapeutics, please visit www.nektar.com.

    Contact:
    Jennifer Ruddock, 650-631-4954
    Nektar Therapeutics

'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... WASHINGTON and NEW YORK ... 2014 As the leading distributor of market ... a new research report by IQ4I Research and Consultancy ... To learn more about IQ4I Research visit: ... Active Pharmaceutical Ingredients Global Market – Forecast ...
(Date:11/26/2014)... Nov. 25, 2014 Reinforcing its commitment to ... (NYSE: PHG AEX: PHIA) today announced ... (FDA) for its IQon Spectral CT , presenting ... kind technology adds a new dimension to Computed Tomography ... to characterize structures based on their material content within ...
(Date:11/26/2014)... , Nov. 25, 2014  Unilife Corporation (NASDAQ: ... injectable drug delivery systems, today announced that its Chairman ... present at the Piper Jaffray 26th Annual Healthcare Conference ... EST on Tuesday, December 2, 2014. ... as a "live" listen only Webcast. To listen, please ...
Breaking Medicine Technology:MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2
... ORLEANS, June 16 Cardinal Health, a,global provider ... and,productivity of health care, today announced that it ... (PET),radiopharmaceuticals for clinical trials., The company,s new ... at the Society of Nuclear Medicine,s (SNM) 55th ...
... the efficacy of RESPeRATE while highlighting ... BERLIN and NEW YORK, June 16 European Society ... Ltd., a medical device,company publicly traded on the Tel-Aviv ... studies and analysis highlighting RESPeRATE,-- the only medical device ...
Cached Medicine Technology:Cardinal Health Expands PET Nuclear Pharmacy Services to Support Clinical Drug Trials 2Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies 2Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies 3Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies 4
(Date:11/26/2014)... (PRWEB) November 26, 2014 The family ... $100,000 to the Mesothelioma Applied Research Foundation (Meso Foundation), ... Meso Foundation’s Patient Travel Grant Program . The ... is to create grant partnerships with organizations that can ... , Mr. Schulze is the founder and chairman emeritus ...
(Date:11/26/2014)... November 26, 2014 The American ... the Association’s new director of meetings and conferences. ... annual meeting, special events and conferences. , ... this post,” said AAA Executive Director Ed Liebow. ... enthusiasm and energy. She was recognized in January ...
(Date:11/26/2014)... Washington, DC (PRWEB) November 26, 2014 ... Inc.’s (AIS) independently published The AIS Report on Blue ... Inc. and WellPoint, Inc. on the varied strategies the ... costs and improve compliance with treatments for sleep apnea, ... The sleep disorder, because it’s linked to increased rates ...
(Date:11/26/2014)... Santa Rosa, California (PRWEB) November 26, 2014 ... be making never before seen reductions in prices of ... and Liposomal Vitamin D3 . Discounts ... only. , GI for Life’s proprietary ColoVite ... leading board-certified gastroenterologists to promote colon health. One easy-to-take ...
(Date:11/26/2014)... Anthropologists have identified concrete recommendations that ... Ebola, improve international support, and pave the way ... Africa. , The report, “Strengthening West African ... Insights,” will be made public during a press ... Fri., Dec. 5, 11 a.m., at the AAA ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:American Anthropological Association Appoints New Director of Meetings and Conferences: Ushma Suvarnakar 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3
... team led by scientists at Cold Spring Harbor Laboratory (CSHL) ... through thousands of candidate hairpin-shaped RNA molecules at a time ... the activity of a target gene. This accomplishment will now ... cellular mechanism that has already been co-opted by scientists for ...
... Foundation has awarded four new grants to help improve ... hepatitis C (HCV) in China and India. The grants ... commitment to reducing hepatitis-related health disparities in Asia to ... grant recipients were announced at the Asian Pacific Association ...
... the U.S. with hepatitis C virus (HCV) are twice as ... without the disease. In fact researchers found only a third ... remaining are either uninsured or not candidates for therapy due ... the March issue of Hepatology , a peer-reviewed journal ...
... in Spanish . , When the family doctor is ... the management of their health problem, especially when it is a ... expectations of their family doctor "listening to them, keeping them informed ... This was the conclusion drawn of a study recently conducted by ...
... study accepted for publication in The Endocrine Society,s Journal ... with fatty liver were five times more likely to develop ... risk seemed to occur regardless of the patient,s fasting insulin ... In recent years, fatty liver has become more appreciated ...
... have often referred to ultrasound technology as the "stethoscope of ... it will one day be as common at the bedside ... a new report in The New England Journal of ... "Current Concepts" article by Yale School of Medicine clinicians Christopher ...
Cached Medicine News:Health News:New method powerfully boosts efficiency of RNA interference (RNAi) in shutting down genes 2Health News:New method powerfully boosts efficiency of RNA interference (RNAi) in shutting down genes 3Health News:Bristol-Myers Squibb Foundation awards nearly $1M to HBV, HCV awareness, prevention and care 2Health News:Bristol-Myers Squibb Foundation awards nearly $1M to HBV, HCV awareness, prevention and care 3Health News:Lack of health insurance limits hepatitis C patients' access to latest antiviral therapy 2Health News:When the doctor is a woman, patients expect them to be involved in decision making 2Health News:Fatty liver may herald impending Type 2 diabetes 2Health News:Bedside ultrasound becomes a reality 2
The ImagingPlanet 70 mm surgical microscope video adapter: Superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Leica surgica...
The ImagingPlanet 80 mm surgical microscope video adapter: superior optical quality and precise engineering make this 80 mm focal length adapter an excellent decision for use with your Leica surgical...
The ImagingPlanet 55 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Zeiss surgical micro...
... Archive Manage and Retrieve ... Optronics DVMR- office, the first ... for the physician's office environment. ... variety of high-resolution cameras for ...
Medicine Products: